[{"id":"1ff726df-4ae8-4795-97b5-a7e91fde5bce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05208307","created_at":"2022-01-26T12:53:35.060Z","updated_at":"2025-02-25T13:12:53.198Z","phase":"Phase 2","brief_title":"Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma","source_id_and_acronym":"NCT05208307","lead_sponsor":"Emory University","biomarkers":" CD4","pipe":" | ","alterations":" Chr t(4;14) • Chr t(14;16)","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • Blenrep (belantamab mafodotin-blmf) • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 10/21/2025","primary_completion_date":" 10/21/2025","study_txt":" Completion: 10/21/2026","study_completion_date":" 10/21/2026","last_update_posted":"2024-08-12"},{"id":"24c91644-22bc-4249-aaa6-106bdc7c0471","acronym":"","url":"https://clinicaltrials.gov/study/NCT03524235","created_at":"2021-01-18T17:21:46.884Z","updated_at":"2024-07-02T16:34:59.315Z","phase":"Phase 1","brief_title":"Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","source_id_and_acronym":"NCT03524235","lead_sponsor":"Noah Merin","biomarkers":" MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression","tags":["MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/18/2018","start_date":" 07/18/2018","primary_txt":" Primary completion: 11/07/2021","primary_completion_date":" 11/07/2021","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-06-04"},{"id":"c2516a83-e25b-4521-afde-eaaf91d0d42c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03441958","created_at":"2021-01-18T16:58:32.149Z","updated_at":"2024-07-02T16:35:20.229Z","phase":"Phase 1/2","brief_title":"ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma","source_id_and_acronym":"NCT03441958","lead_sponsor":"Ciusss de L'Est de l'Île de Montréal","biomarkers":" CD34","pipe":" | ","alterations":" Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • Zemcelpro (dorocubicel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/07/2018","start_date":" 03/07/2018","primary_txt":" Primary completion: 10/28/2023","primary_completion_date":" 10/28/2023","study_txt":" Completion: 10/17/2025","study_completion_date":" 10/17/2025","last_update_posted":"2024-02-08"},{"id":"13d940c3-64f2-4c13-a92c-5be14974fb4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499808","created_at":"2021-01-18T17:13:44.637Z","updated_at":"2024-07-02T16:35:24.603Z","phase":"Phase 2","brief_title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","source_id_and_acronym":"NCT03499808","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" NPPB","pipe":" | ","alterations":" Chr t(11;14) • Chr t(4;14) • Chr t(14;16)","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sarclisa (isatuximab-irfc)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/06/2018","start_date":" 06/06/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-04"},{"id":"6c9623a6-4573-485b-b022-26e539880a69","acronym":"A061202","url":"https://clinicaltrials.gov/study/NCT02004275","created_at":"2021-01-18T09:09:12.624Z","updated_at":"2025-02-25T14:34:26.703Z","phase":"Phase 1/2","brief_title":"Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT02004275 - A061202","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CYP1A2","pipe":" | ","alterations":" Chr t(14;16) • Chr del(1p)","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(14;16) • Chr del(1p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Ninlaro (ixazomib) • dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":"","study_completion_date":"","last_update_posted":"2023-12-01"},{"id":"79b87011-f88c-4a4b-b57c-fa97cf0c37d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02308280","created_at":"2022-01-21T21:58:53.578Z","updated_at":"2024-07-02T16:35:32.703Z","phase":"Phase 2","brief_title":"Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients","source_id_and_acronym":"NCT02308280","lead_sponsor":"Maisonneuve-Rosemont Hospital","biomarkers":" HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 09/27/2018","primary_completion_date":" 09/27/2018","study_txt":" Completion: 09/27/2023","study_completion_date":" 09/27/2023","last_update_posted":"2023-10-19"},{"id":"941edf4a-6b54-4d8a-9d5f-0ece5295def7","acronym":"Immuno-PRISM","url":"https://clinicaltrials.gov/study/NCT05469893","created_at":"2022-07-22T12:56:51.323Z","updated_at":"2024-07-02T16:35:41.515Z","phase":"Phase 2","brief_title":"Immuno-PRISM (PRecision Intervention Smoldering Myeloma)","source_id_and_acronym":"NCT05469893 - Immuno-PRISM","lead_sponsor":"Irene Ghobrial, MD","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr t(4;14) • Chr t(14;16)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • Tecvayli (teclistamab-cqyv)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/10/2022","start_date":" 08/10/2022","primary_txt":" Primary completion: 07/31/2030","primary_completion_date":" 07/31/2030","study_txt":" Completion: 07/31/2030","study_completion_date":" 07/31/2030","last_update_posted":"2023-08-01"},{"id":"8e484efc-2bb4-4551-a333-691298e0bf81","acronym":"","url":"https://clinicaltrials.gov/study/NCT05767359","created_at":"2023-03-14T14:01:36.331Z","updated_at":"2024-07-02T16:35:45.349Z","phase":"Phase 2","brief_title":"CAR- PRISM (PRecision Intervention Smoldering Myeloma)","source_id_and_acronym":"NCT05767359","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr t(4;14) • Chr t(14;16)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Carvykti (ciltacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 01/15/2026","primary_completion_date":" 01/15/2026","study_txt":" Completion: 01/15/2040","study_completion_date":" 01/15/2040","last_update_posted":"2023-06-19"},{"id":"d734f8a8-ae63-465f-9e00-b08e9703425a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05422027","created_at":"2022-06-16T14:03:56.923Z","updated_at":"2024-07-02T16:35:54.710Z","phase":"Phase 1/2","brief_title":"Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma","source_id_and_acronym":"NCT05422027","lead_sponsor":"Xia Zhongjun","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr t(4;14) • Chr t(14;16)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-02-27"},{"id":"57d644a2-7988-4d7c-b469-e62a58aafbfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02960646","created_at":"2021-01-18T14:32:35.822Z","updated_at":"2024-07-02T16:35:55.351Z","phase":"Phase 1","brief_title":"Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","source_id_and_acronym":"NCT02960646","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • DNMT3A • ASXL1 • KMT2A • TET2 • PHF6","pipe":" | ","alterations":" FLT3 mutation • DNMT3A mutation • Chr t(4;14) • Chr t(14;16) • MLL rearrangement","tags":["FLT3 • DNMT3A • ASXL1 • KMT2A • TET2 • PHF6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • DNMT3A mutation • Chr t(4;14) • Chr t(14;16) • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/18/2017","start_date":" 01/18/2017","primary_txt":" Primary completion: 02/13/2023","primary_completion_date":" 02/13/2023","study_txt":" Completion: 02/13/2023","study_completion_date":" 02/13/2023","last_update_posted":"2023-02-16"},{"id":"b49f9a71-79b2-4ad4-99ad-e4f72ade1673","acronym":"","url":"https://clinicaltrials.gov/study/NCT05722405","created_at":"2023-02-10T15:00:18.286Z","updated_at":"2024-07-02T16:35:55.821Z","phase":"Phase 4","brief_title":"Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma","source_id_and_acronym":"NCT05722405","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr t(4;14) • Chr t(14;16)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Ninlaro (ixazomib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2023-02-10"},{"id":"de5530b7-3c90-4098-ab6f-1c6d59a6ad9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00995059","created_at":"2021-01-18T03:53:19.250Z","updated_at":"2024-07-02T16:35:58.166Z","phase":"Phase 1/2","brief_title":"Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma","source_id_and_acronym":"NCT00995059","lead_sponsor":"Mayo Clinic","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" Chr t(14;16)","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • sirolimus • melphalan"],"overall_status":"Withdrawn","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-01-05"},{"id":"cc091dc8-bab0-4b9b-8651-cd27049d0124","acronym":"BMT CTN 1302","url":"https://clinicaltrials.gov/study/NCT02440464","created_at":"2021-01-18T11:41:28.818Z","updated_at":"2024-07-02T16:35:58.276Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)","source_id_and_acronym":"NCT02440464 - BMT CTN 1302","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr t(4;14) • Chr t(14;16) • Chr t(14;20)","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14) • Chr t(14;16) • Chr t(14;20)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Ninlaro (ixazomib) • melphalan • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2023-01-04"},{"id":"03f05543-0558-4406-af40-e682d4bba542","acronym":"","url":"https://clinicaltrials.gov/study/NCT01119066","created_at":"2021-01-18T04:26:17.749Z","updated_at":"2024-07-02T16:36:05.975Z","phase":"Phase 2","brief_title":"HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies","source_id_and_acronym":"NCT01119066","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":" | ","alterations":" Chr t(4;14) • Chr t(14;16) • Chr t(15;17)","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14) • Chr t(14;16) • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • clofarabine • melphalan • fludarabine IV • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 422","initiation":"Initiation: 05/03/2010","start_date":" 05/03/2010","primary_txt":" Primary completion: 03/30/2021","primary_completion_date":" 03/30/2021","study_txt":" Completion: 03/30/2021","study_completion_date":" 03/30/2021","last_update_posted":"2022-08-05"},{"id":"57594000-327e-4420-94e5-e251565ffa38","acronym":"","url":"https://clinicaltrials.gov/study/NCT01131169","created_at":"2021-01-18T04:29:40.279Z","updated_at":"2024-07-02T16:36:19.930Z","phase":"Phase 2","brief_title":"Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions","source_id_and_acronym":"NCT01131169","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1","pipe":" | ","alterations":" Chr t(4;14) • Chr t(14;16)","tags":["HLA-DRB1 • HLA-DQB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 05/15/2020","primary_completion_date":" 05/15/2020","study_txt":" Completion: 05/15/2020","study_completion_date":" 05/15/2020","last_update_posted":"2021-12-02"}]